USES: This product contains 2 drugs (betamethasone and calcipotriene) and is used to treat psoriasis of the scalp. Some brands of this medication are also used to treat psoriasis on the body. Calcipotriene 0.005 and betamethasone dipropionate 0.064 ointment is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. Factors that predispose a patient to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, concomitant use of more than one corticosteroid-containing product, use of occlusive dressings, altered skin barrier, liver failure, and young age. Brand Name: Enstilar, Taclonex, Taclonex Scalp, Dovobet. Betamethasone and calcipotriene topical foam or ointment should be used only on the skin and only by adults. Do not use betamethasone and calcipotriene topical to treat any condition that has not been checked by your doctor.
Calcipotriene is used on the skin and scalp to treat plaque psoriasis. OBJECTIVE: The efficacy of the two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate applied once daily in psoriasis has been demonstrated in phase III trials but no randomised clinical trial comparing all commonly used topical treatments exists. USES: This medication is used to treat psoriasis. This product contains 2 drugs. Scalp psoriasis causes red, raised, scaly patches that may extend from the scalp to the forehead and the back of the neck and ears. This is a combination product that contains 2 medications: calcipotriol and betamethasone. The gel form of this medication is used to treat psoriasis that has developed on the scalp and body. Calcipotriol – betamethasone gel should not be applied from 12 hours before to 12 hours after chemical hair treatments such as dyes or perms.
This is a combination product that contains 2 medications: calcipotriol and betamethasone. Betamethasone belongs to the class of medications known as corticosteroids and works by reducing itching and inflammation. The gel form of this medication is used to treat psoriasis that has developed on the scalp and body. Topical treatment with vitamin D analogs and corticosteroids is the mainstay of first-line therapy for patients with localized psoriasis. 13The fixed-combination product of calcipotriene plus betamethasone dipropionate has been uniquely formulated to overcome the inherent instability of the vitamin D analog in the presence of the acidic betamethasone dipropionate and to optimize the delivery of both agents in a once-daily formulation. Psoriasis of the scalp affects about 50 of patients. The primary infection-fighting units are two types of white blood cells: lymphocytes and leukocytes. Because these drugs are also used to treat psoriasis, this rebound effect is of particular concern. Taclonex, an ointment containing both calcipotriol and betamethasone, is available for the treatment of adults with psoriasis.
Calcipotriene (on The Skin)
It has 2 year stability at room temperature, but should be used within 3 months of opening. The ointment form of this medication is used to treat psoriasis that. Daivobet gel is used as topical treatment of body and scalp psoriasis. Topical corticosteroids are the mainstay of psoriasis treatment in the United States. Less potent drugs are used for mild-to-moderate psoriasis. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. Conclusion: Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality. Since 2008 (approval for use on the scalp in Canada and the USA) and 2004 (approval for use on the remainder of the skin surface), fixed combinations of calcipotriol/betamethasone dipropionate have been approved for the treatment of psoriasis (gel and ointment). When using calcipotriol containing medicinal products, the maximum daily dose should not exceed 15 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30 (see section 4.